Compare Crispr Therapeutics AG (CRSP) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Vanguard High Dividend Yield ETF — how do they compare? Crispr Therapeutics AG trades at $51.28 (market cap $4.97B), while Vanguard High Dividend Yield ETF trades at $160.24. The key difference: Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | VYM | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | — |
52-Week High | $76.78 | $161.17 |
52-Week Low | $44.34 | $132.90 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
VYM trades at $160.86, down slightly by 0.12% today, with a bullish technical outlook supported by moving averages. The ETF maintains strong investor interest as a dividend income vehicle with $78.33 billion in assets and 618 holdings. Recent news highlights its role in retirement portfolios for tax-efficient income generation, though some articles question whether alternative funds offer better yields or performance.
The outlook remains positive for income-focused investors seeking broad diversification and low costs. Key risks include interest rate sensitivity and potential dividend sustainability during market downturns. Analyst sentiment favors VYM for long-term dividend growth despite current yield comparisons with competing ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
